Clinical observations of six advanced refractory ovarian cancer cases treated with apa-tinib
10.3969/j.issn.1000-8179.2018.07.202
- VernacularTitle:阿帕替尼治疗6例晚期难治性卵巢癌的临床观察
- Author:
Lili WANG
1
;
Xin LI
;
Dingkun HOU
;
Hao WANG
;
Haitao WANG
Author Information
1. 天津医科大学第二医院肿瘤科
- Keywords:
overian cancer;
apatinib;
clinical efficacy;
adverse reactions
- From:
Chinese Journal of Clinical Oncology
2018;45(7):362-365
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the efficacy and the adverse reactions of conventional treatment-failed advanced refractory ovarian cancer cases after treatment with apatinib.Methods:Six patients enrolled in the Second Hospital of Tianjin Medical University from June 2015 to October 2015 received treatment with apatinib. Treatment efficacy was evaluated by imaging and analysis of tumor markers,including CA125,CEA,and NSE.Results:The age range of the six patients was 48-71 years(median:55 years).Their histopath-ological subtypes included poorly differentiated serous cystadenocarcinoma(4/6),borderline papillary adenoma(1/6),and clear cell carcinoma(1/6).Clinical evaluation of patients revealed no cases with complete remission,two cases with partial response,one case with stable disease,and three cases with progressive disease.The objective response rate was 33%(2/6)and the disease control rate was 50%(3/6).In all patients,the main side effects were hypertension and hand-foot syndrome,which were controlled.Conclusions:The treatment of conventional treatment-failed advanced refractory ovarian cancer with apatinib has better exact effects,and medical toxicity can be controlled.In the future,to seek more effective treatment strategies,the mechanism of apatinib in the treatment of ad-vanced ovarian cancer should be further explored.
